ENANTA PHARMACEUTICALS

Company snapshot

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseas

• 34 active pipeline program(s) linked via ClinicalTrials.gov.
• 218 US patent(s) indexed to this assignee profile.
• 34 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ENANTA PHARMACEUTICALS. Not investment advice.

• Peer + 0 momentum

  Aligos Therapeutics

  TA overlap score 32.8

• Peer + 0 momentum

  Atea Pharmaceuticals

  TA overlap score 27.4

• Peer + 0 momentum

  Madrigal Pharmaceuticals EU

  TA overlap score 23.2

Recent activity

Latest pipeline, patent, and corporate events for ENANTA PHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   Fluconazole — Phase 1

2. Jun 8, 2026 Clinical update

   EDP-305 Dose 1 — Phase 2

3. Jun 8, 2026 Clinical update

   EDP-938 — Phase 2

4. Jun 8, 2026 Clinical update

   EDP-514 — Phase 1

5. Jun 8, 2026 Clinical update

   EDP-235 — Phase 2

View all clinical trial activity →

• What is ENANTA PHARMACEUTICALS?

  Enanta Pharmaceuticals is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker ENTA. Primary therapeutic focus areas include RSV Infection, NASH - Nonalcoholic Steatohepatitis, Non-Alcoholic Steatohepatitis, Hepatitis C, NASH. NovaPharmaNews links

• Is ENANTA PHARMACEUTICALS publicly traded?

  Yes. ENANTA PHARMACEUTICALS is listed with ticker ENTA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ENANTA PHARMACEUTICALS develop or market?

  We link 15 drug profile(s) where ENANTA PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/enanta-pharmaceuticals-inc#company-drugs.

• What are the latest developments for ENANTA PHARMACEUTICALS?

  In the last 12 months our linked public records show 34 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does ENANTA PHARMACEUTICALS focus on?

  ENANTA PHARMACEUTICALS focuses on RSV Infection, NASH - Nonalcoholic Steatohepatitis, Non-Alcoholic Steatohepatitis based on our analysis of their pipeline programs and drug development activities.